<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01476956</url>
  </required_header>
  <id_info>
    <org_study_id>RA BIODAM</org_study_id>
    <nct_id>NCT01476956</nct_id>
  </id_info>
  <brief_title>Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography</brief_title>
  <official_title>Prospective Validation of Soluble Biomarkers as Predictors of Structural Damage in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Research &amp; Education in Arthritis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Research &amp; Education in Arthritis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recruited patients will include those about to begin Disease-Modifying Antirheumatic Drug)
      DMARD therapy or about to change DMARD therapy.

      Disease activity will be monitored systematically every 3 months by the Disease Activity
      Score.

      Changes in standard DMARD and/or anti-Tumor Necrosis Factor α (anti-TNFα) therapy will be
      made according to specific recommendations for patients receiving these therapies.

      Biomarker samples will be collected every 3 months and prior to change in DMARD and/or
      anti-TNF therapy as defined below. A blood sample (40 ml) for serum will be taken for
      biomarker studies and processed according to the international committee of Outcome Measures
      in Rheumatology (OMERACT) recommendations for the minimal handling of biomarker samples. A
      urine sample (20 ml) will also be taken and processed as for serum.

      Radiography (X-rays) will be conducted every 6 months (baseline, 6, 12, 18, 24 months).

      Patients will be followed for 2 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment is Disease Activity Score (DAS) driven. Changes in standard DMARD and/or anti-TNFα
      therapy will be implemented according to 2010 European League against Rheumatism (EULAR)
      recommendations which state a target of remission (DAS44 &lt;1.6) for patients receiving
      standard DMARD therapy in the setting of early disease and a target of low disease activity
      state (LDAS) (DAS44 ≤2.4) for patients receiving anti-TNFα therapy in the setting of
      established disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the independent predictive validity of several soluble biomarkers for predicting structural damage in Rheumatoid Arthritis (RA).</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish which modifiable clinical and laboratory predictors used in routine practice individually and in combination, have the strongest and the most consistent association with change in radiographic damage in patients on standard RA therapy.</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>RA patients on standard DMARD therapy</description>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  whole blood/serum

        -  urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        RA patients from rheumatologists' clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (selected):

          -  18 years of age or older

          -  RA according to the 2010 Rheumatoid Arthritis Classification Criteria

          -  Joint symptoms for ≥ 3 months prior to screening

          -  DAS44 &gt; 2.4

          -  About to start DMARD therapy (methotrexate, salazopyrin, hydroxychloroquine,
             chloroquine, leflunomide) or

               -  increased dose of methotrexate by ≥10 mg weekly to a maximum dose of 25mg weekly
                  (if already receiving &gt;15mg will require add-on DMARD/anti-TNF or switch to
                  alternative DMARD),

               -  add-on of alternative DMARD,

               -  switch to alternative DMARD,

               -  start of first anti-TNFα agent (adalimumab, etanercept, infliximab, certolizumab
                  pegol, golimumab)

          -  If already on DMARD therapy this has been stable for the 3 months prior to the
             baseline visit

          -  If already on systemic steroid, dose must be stable (prednisone ≤ 7.5mg/day) for 1
             month prior to the baseline visit

          -  Patient will be available for follow up for a minimum of 24 months from the baseline
             visit

        Exclusion Criteria (selected):

          -  Intra-articular steroid injection within 4 weeks prior to the baseline visit

          -  Prior treatment with anti-TNFα or other biological agent (rituximab, abatacept,
             tocilizumab)

          -  Malignancy within past 5 years (other than basal cell carcinoma that has been
             adequately treated or excised, squamous cell cancer of the skin, and cervical
             carcinoma in situ)

          -  History of:

               -  Serious infection (defined as requiring parenteral antibiotics or
                  hospitalization) within 3 months prior to the baseline visit;

               -  Active tuberculosis or history of tuberculosis without documented curative
                  treatment and/or positive tuberculin reaction to PPD (Purified Protein
                  Derivative)

          -  For patients starting anti-TNF therapy, a positive TB screening test and no record of
             effective prophylaxis according to local expert recommendations

          -  Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter P. Maksymowych, MD</last_name>
    <role>Study Director</role>
    <affiliation>CaRE Arthritis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Arthritis Center, Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologist Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, Columbia University, College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Allergy, Immunology and Rheumatology, University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology, University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center, University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial University</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Research Group</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Osteoporosis Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Copenhagen University Hospital at Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Rheumatologie-CHU Bordeaux Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Le Roux Liana, Centre d'Investigation Clinique</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre des Consultations et imagerie de l'appareil locomoteur service de rheumatologie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departement de rheumatologie, Hopital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologie B, Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infirmiere de Recherche Clinique, CHU de Toulouse, Centre de Rheumatologie, Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik, Department of Rheumatology and Clinical Immunology</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>D-61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology/Clinical Immunology, Medizinische Klinik-Rheumatologie und Klinische Immunologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum der Friedrich-Schiller-Universitat Jena, Klinik für Innere Medizin III/Rheumatologie/Osteologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Spieler</name>
      <address>
        <city>Zerbst</city>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, St. Vincents University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Centre</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ferrara</name>
      <address>
        <city>Ferrara</city>
        <zip>44121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Day Hospital Reumatologia</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Milan</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of the Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, University of Verona</name>
      <address>
        <city>Verona</city>
        <zip>37067</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre/University of Amsterdam</name>
      <address>
        <city>Amesterdam</city>
        <zip>1100 DE Amsterdam</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam VU University Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>0157 AB Amsterdam</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre/University of Amsterdam and Atrium Medical Centre Heerlen</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC Heerlen</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afdeling Reumatologie, Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC Leiden</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Diakonhjemmet Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

